As we think about the path forward for economic policy in the aftermath of COVID-19, this month’s commentary examines the playbook at the disposal of global policymakers.
During the month of April financial markets partially recovered from the most volatile month on record and one of the swiftest and most severe re-pricing of risk assets experienced during the year’s first quarter.
On May 11, 2020 the first ever randomized study in obstructive, hypertrophic cardiomyopathy had decisively positive results. The news had a clinical-stage biotech company’s shares up considerably. This is the second major win for industry in developing precision cardiology medicines.